PharmaLive

Pfizer Raises 2019 Forecast As Sales Of Cancer Drug, Heart Medicine Surge

Sanofi Confident For 2019 Despite Q3 Sales Slip

J&J Says New Tests Find No Asbestos In Same Baby Powder Bottle That Sparked Recall

GlaxoSmithKline Starts Late-Stage Trial For Experimental Antibiotic

Amgen Posts Higher Biosimilar Sales for Q3 2019, Ends Neuroscience Program

Allergan Settles Alzheimer's Therapy Lawsuit For $750 Million

Gilead, Galapagos' JAK Inhibitor Stumbles In Mid-Stage Lupus Study

FDA Approves Biogen's Vumerity For Multiple Sclerosis

Japanese Drugmaker Takeda Cuts Full-Year Fiscal 2019 Loss Forecast

Bristol-Myers Squibb’s top two products just keep growing, and now the company may be adding a $10 billion brand via the planned acquisition of Celgene.

Johnson & Johnson management has outlined a strategy to deliver above-market, compound annual growth for the company’s pharmaceutical business through 2023.

Merck’s extraordinary success with the immuno-oncologic Keytruda has pushed the company back to the pinnacle of the pharma industry.

One of the world’s great biotechs just keeps churning out innovative new drugs and profits, even after the company’s roller-coaster Sovaldi/Harvoni experience.

Amgen continues to set the stage for the future after a record-setting 2018, strengthening the company’s long-term ability to innovate, compete and grow.

Before his retirement in September 2019, CEO Olivier Brandicourt oversaw four years of Sanofi reshaping itself to overcome the effect of patent expirations for the company’s leading medicines.

Pfizer's 2019 features a new executive chairman, the completion of a consumer health joint venture, the prospect of merging its legacy medicines company with Mylan, and an $11.4 billion biotech acquisition.

Merck Loses Bid To Revive $2.54 Billon Patent Verdict Against Gilead

Novartis' Zolgensma Study Halted By FDA Amid Safety Questions

Bristol-Myers Posts Better-Than-Expected Q3 2019 Results, Opdivo Growth Slows

AstraZeneca is rebuilding the company’s strength by making oncology one of the primary focuses in R&D and launching new drugs and indications in this therapy area.

GlaxoSmithKline’s three long-term priorities are designed to create long-term value for patients, consumers, and shareholders.

Novartis is investing in the most promising frontiers of science, the most exciting innovations in the business of medicine, and the most significant healthcare needs.

The world’s leading prescription drug Humira will still bring in plenty of revenue over the next few years, but AbbVie has already begun moving on to what’s next.

As Bayer battles rulings and upcoming trials over the safety of the weedkiller Roundup, the company is continuing to expand R&D capabilities in pharmaceuticals.

Roche’s newer pharmaceutical products are generating stellar performances and have the company well-positioned for future growth.

The Healthcare Businesswomen’s Association’s 2019 Annual Conference will be held in San Diego on November 11-12.